Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 10Lung Neoplasms 3Neuroblastoma 2Recurrence 1Non-Small Cell Lung Cancer ALK-positive 1Non Small Cell Lung Cancer Metastatic 1Neoplasm Metastasis 1Meningeal Carcinomatosis 1Glioma 1Glioblastoma 1Ganglioneuroblastoma 1Diffuse Intrinsic Pontine Glioma 1Carcinoma 1Brain Neoplasms 1Astrocytoma 1Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer 1Advanced Non-Small Cell Lung Cancer 1ALK Positive Non-small Cell Lung Cancer 1

Interventions

Temozolomide 43Magnetic Resonance Spectroscopy 41Radiotherapy 23Specimen Handling 18Biopsy 13X-Rays 10Radiation 10trametinib 8Bevacizumab 8Nivolumab 7Blood Specimen Collection 7olaparib 6fluorodopa F 18 6dabrafenib 6Radiotherapy, Intensity-Modulated 6Phantoms, Imaging 6Nuclear Medicine Department, Hospital 6pembrolizumab 5abemaciclib 5Standard of Care 5Lomustine 5ulixertinib 4larotrectinib 4ivosidenib 4erdafitinib 4Surgical Procedures, Operative 4Dianhydrogalactitol 4Cyclophosphamide 4Aminolevulinic Acid 4vorasidenib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Glioma × lorlatinib × 1 year × Clear all
NCT06333899 2026-03-12

Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion

Nationwide Children's Hospital

Phase EARLY_PHASE1 Recruiting
15 enrolled
CNS

Diffuse Intrinsic Pontine Glioma, Astrocytoma, Glioblastoma, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡